REPL NASDAQ
Replimune Group, Inc.
1W: +5.7%
1M: -18.2%
3M: +13.9%
YTD: +46.9%
1Y: +210.4%
3Y: -21.3%
5Y: -59.5%
$13.07
-0.38 (-2.83%)
Weekly Expected Move ±6.5%
$11
$12
$13
$14
$15
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Compass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Replimune Group, Inc. (NASDAQ:REPL) Receives $12.00 Consensus PT from Analysts
Squarepoint Ops LLC Takes Position in Replimune Group, Inc. $REPL
Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune Group, Inc. $REPL Shares Acquired by Bank of America Corp DE
Hsbc Holdings PLC Invests $1.03 Million in Replimune Group, Inc. $REPL
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group Stock Short Interest Rises to 57.95% - Quiver Quantitative
Cantor Fitzgerald reiterates Replimune stock rating on launch potential - Investing.com
Replimune Group (NASDAQ:REPL) Sets New 12-Month High - Here's Why - MarketBeat
REPL Aug 2026 1.500 call (REPL260814C00001500) stock price, news, quote and history - Yahoo Finance UK
Baker Bros. Advisors (NASDAQ: REPL) details 11.8% stake and warrant buys - stocktitan.net
REPL Aug 2026 5.500 put (REPL260814P00005500) Stock Price, News, Quote & History - Yahoo! Finance Canada
Replimune Group (NASDAQ:REPL) Shares Gap Up on Analyst Upgrade
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Stocktwits
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
Replimune Group (REPL): Goldman Sachs units disclose 5.3% beneficial stake - stocktitan.net
How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For New Melanoma Therapy - simplywall.st
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’ - TradingView
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group - Morningstar
Replimune Group (NASDAQ:REPL) Shares Gap Up After Analyst Upgrade - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months - Yahoo! Finance Canada
Replimune Prices $150 Million Common Stock and Pre-Funded Warrant Offering - Quiver Quantitative
Replimune Group (REPL) Wins FDA Approval, Is The Valuation Still Too Rich? - simplywall.st
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Stocktwits
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)
REPL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today?
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - TradingView
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval
Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week?
Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next
This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - finance.yahoo.com
Replimune surges on positive AdCom vote on lead drug
Why Is REPL Stock Soaring 127% After Hours Today?
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Four stock-moving events to watch as FDA revives AdComs
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Regenxbio, Replimune among gainers after FDA U-turn on UniQure
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today
Why Is Replimune Stock Gaining Monday?
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune got another attempt at lead drug after White House intervention: WSJ
12 Health Care Stocks Moving In Friday's Intraday Session
Replimune, Dell Technologies, NetApp And Other Big Stocks Moving Higher on Friday
Replimune surges on plans to resubmit lead drug for FDA review
Replimune Gets Third Try at FDA Approval After Makary Departure - WSJ
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
FDA head Makary defends drug application rejections amid criticism
What's Going On With Replimune Stock On Tuesday?
FDA said to have named Katherine Szarama as acting CBER chief
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
12 Health Care Stocks Moving In Thursday's Intraday Session
Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)
RFK Jr. says no hand in rejecting Replimune’s lead asset
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of “Reduce” from Brokerages
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
FDA Rejection Sparks Questions On Replimune Drug Approval Path
12 Health Care Stocks Moving In Monday's Intraday Session
Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Street sours on Replimune as stock hits all-time low on melanoma drug rejection
Biggest stock movers Monday: REPL, GS, LEG and more
Dow Dips Over 350 Points; Goldman Sachs Posts Upbeat Earnings
This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
12 Health Care Stocks Moving In Monday's Pre-Market Session
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Biggest stock movers Monday: REPL, BKR, and more
Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1
Replimune Group (NASDAQ:REPL) Stock Price Up 6.2% – Here’s Why
Replimune plans layoffs as FDA rejects cancer drug
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short
12 Health Care Stocks Moving In Friday's Intraday Session
Replimune under pressure as FDA rejects lead asset again
What's Going On With Replimune Stock Friday?
Stock Traders Purchase Large Volume of Replimune Group Put Options (NASDAQ:REPL)
FDA Review Looms As Replimune Faces Weak Technical Setup
12 Health Care Stocks Moving In Wednesday's Intraday Session
Replimune Group (NASDAQ:REPL) Trading Down 6.7% on Insider Selling